mycophenolate mofetil + angiotensin blockade

The therapeutic regimen referred to as **mycophenolate mofetil + angiotensin blockade** consists of the immunosuppressive agent mycophenolate mofetil (MMF) administered as an add-on therapy to standard-of-care angiotensin blockade (using either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers). This specific combination was evaluated in a Phase 4 clinical trial conducted by **The University of Hong Kong** (Hong Kong Immunoglobulin A Study Group) for patients with **IgA nephropathy** who exhibited persistent heavy proteinuria despite receiving maximal doses of angiotensin blockade. Mycophenolate mofetil is a small molecule prodrug of mycophenolic acid, which acts by inhibiting inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for the de novo synthesis of guanosine nucleotides in T and B lymphocytes. By selectively suppressing lymphocyte proliferation, MMF aims to reduce the immune-mediated glomerular inflammation and injury characteristic of IgA nephropathy, while the background angiotensin blockade provides hemodynamic and anti-proteinuric effects by modulating the renin-angiotensin system.

Brand names

CellCept

Other names

angiotensin blockade-The University of Hong Kong-IgA nephropathyMMF + ACEI/ARBmycophenolate mofetil plus angiotensin blockade